{
}
Morgan Stanley has upgraded Zealand Pharma to Overweight, citing the long-term potential of its obesity treatment, petrelintide, following a partnership with Roche. Despite current market challenges, analysts believe the obesity market opportunity remains robust, with petrelintide positioned as a leading therapeutic. The recent decline in Zealand's stock price is seen as an attractive entry point for investors, with potential upside from upcoming data and the partnership's implications for future sales.
UBS AG has maintained a "Buy" rating on Roche shares with a target price of 338 francs, highlighting the company's partnership with Zealand Pharma for the obesity treatment Petrelintide. Analyst Matthew Weston noted Roche's commitment to expanding obesity treatment mechanisms, following its acquisition of a GLP1/GIP treatment. Roche shares rose 5.3% to CHF 312.10, indicating an 8.3% upside potential from the target price, with a 22.2% increase since the start of 2025.
Roche has entered a collaboration with Zealand Pharma, investing up to $5.3 billion to develop a new generation of anti-obesity injections. This strategic move marks Roche's significant commitment to the lucrative weight loss market, following interest from several pharmaceutical companies.
Zealand Pharma A/S reported a Q3 loss of $0.56 per share, outperforming the consensus estimate of a $0.62 loss, but revenues of $0.65 million fell short by 75.75% compared to expectations. The company has seen a 125.2% stock increase this year, despite mixed earnings outlooks leading to a Zacks Rank #3 (Hold). Current estimates for the next quarter are -$0.81 EPS on $3.01 million in revenues.
Novo Nordisk plans to seek regulatory approval for semaglutide as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) after positive Phase 3 trial results. The study showed significant improvements in liver scarring and resolution of MASH among patients receiving semaglutide compared to placebo. Despite the promising findings, analysts remain cautious about its competitive edge in the MASH treatment landscape.
Zealand Pharma A/S
Companies
| Symbol | ZEAL |
| Name | Zealand Pharma A/S |
| Currency | USD |
| Sector | Health Care |
| IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences |
| Industry | Biotechnology |
| Market | NASDAQ Global Select |
| Country | Denmark |
| State | |
| City | Copenhagen |
| Zipcode | 2860 |
| Website | http://www.zealandpharma.com |
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Morgan Stanley upgrades Zealand Pharma citing long-term obesity market potential
Euro
Danish Krone
United States Dollar
Zealand Pharma A/S
Hoffmann-La Roche AG
Novo Nordisk A/S
DNK
USA
Show more
09:56 21.03.2025
ubs rates roche shares buy with target price of 338 francs
17:03 14.03.2025
Roche invests 5.3 billion in Zealand Pharma for anti-obesity collaboration
17:38 12.03.2025
zealand pharma reports q3 loss and misses revenue estimates significantly
13:05 07.11.2024
novo seeks approval for semaglutide as treatment for liver disease
United States Dollar
Eli Lilly and Company
Akero Therapeutics, Inc.
Novo Nordisk A/S
Zealand Pharma A/S
Intercept Pharmaceuticals Inc.
Madrigal Pharmaceuticals, Inc.
Boehringer Ingelheim KG
89bio, Inc.
DNK
Thomas Smith
Andy Hsieh
Brian Abrahams
Martin Holst Lange
William Blair
Show more
15:45 01.11.2024
Trending
Subcategory
Stock Market Updates
Corporate News
Industry Trends
Banking Regulations
Finance Mergers & Acquisitions
Global Financial Events
Retail and Consumer Goods
Central Bank Actions
GDP Growth & Recession Forecasts
CEO Changes
Global Trade Developments
Industry Mergers & Acquisitions
Financial Scams and Security
Market Analysis and Predictions
Inflation and Monetary Impact
Government Policies
Government Economic Policies
Supply Chain Management
Domestic Politics
Workplace Trends
Countries:
Companies:
The Goldman Sachs Group, Inc.
JPMorgan Chase & Co.
Tesla, Inc.
Apple Inc.
Bank of America Corporation
Barclays PLC
Wells Fargo & Company
Citigroup Inc.
Deutsche Bank Money Market PP
Morgan Stanley
Huawei Technologies CO. Ltd.
Lloyds Banking Group plc
Credit Suisse Strategic Income I
AXA SA
Safran SA
Banco Santander, S.A.
Novartis AG
NVIDIA Corporation
Swiss Re AG
Beazley plc
Currencies:
United States Dollar
Euro
Chinese Yuan
British Pound Sterling
Swiss Franc
Japanese Yen
Indian Rupee
Russian Ruble
Canadian Dollar
Australian Dollar
United Arab Emirates Dirham
Indonesian Rupiah
Saudi Riyal
South Korean Won
Danish Krone
Offshore Chinese Yuan
Hong Kong Dollar
Mexican Peso
Malaysian Ringgit
Vietnamese Đồng
People: